April 20, 2026 · Form 4 insider transaction
BAIN CAPITAL INVESTORS LLC bought 8,398,438 shares of Kailera Therapeutics, Inc. at $16.00 per share, a transaction worth $134.38M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 0 days after the transaction.
Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus").; Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.